Platinum/etoposide regimens carry an intermediate risk of febrile neutropenia in extensive-stage small cell lung cancer ...

Mogamulizumab (Poteligeo) was associated with durable real-world treatment outcomes in patients with mycosis fungoides (MF) ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...

Elevar Therapeutics and Hengrui Pharma have resubmitted applications to the FDA seeking approval of rivoceranib plus ...

Al-Ola Abdallah, MD, discusses IMiD-based holding therapy before leukapheresis and its safety in patients with myeloma receiving CAR T-cell therapy. Five myeloma experts share their top takeaways from ...

Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he ...

Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor and how ...

The FDA has allowed the launch of a phase 2 study of MT027, an allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Paula Rodriguez-Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of high-risk smoldering myeloma. High-risk smoldering multiple myeloma ...